Table Info

Table 3.

Receptor complexes containing receptors involved in excitotoxicity-associated processes

Cell location	Receptor complex	Observed interaction	References
Neurons	AMPA-IFNγ AMPA-D₂ NMDA-D₁ NMDA-D₂ NMDA-MOR NMDA-A_2A NMDA-mGluR₅ NMDA-D₁-H₃ mGluR₁-mGluR₅ mGluR₂-mGluR₃ mGluR₂-mGluR₄ mGluR₂-mGluR₇ mGluR₁-A₁ mGluR₂-5HT_2A mGluR₅-A_2A mGluR₅-D₂ mGluR₅-MOR A_2A-D₂-mGluR₅ A_2A-D₂ A₁-A_2A GABA_A-D₅ A_2A-GR GR-MR ER_α-mGluR₁	Enhanced AMPA signaling Reduced AMPA signaling Reduced NMDA signaling Reduced NMDA signaling Enhanced NMDA signaling Cross-antagonism Dependent on scaffold proteins Cross-antagonism Asymmetric Asymmetric Asymmetric Asymmetric Reduced mGluR₁ signaling Enhanced mGluR₂ signaling Synergistic Reduced D₂ signaling Delayed MOR desensitization Reduced D₂ signaling Antagonistic Reduced A₁ affinity Synergistic Reduced GR activity Synergistic Increased internalization	[150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [159] [160] [161] [162] [163, 164] [165] [166] [23] [8] [167] [168] [169] [170] [171]
Astrocytes	A_2A-D₂ A₁-A_2A A₁-P2Y₁ A_2A-OTR D₂-OTR	Antagonistic Antagonistic A₁ desensitization Antagonistic Synergistic	[172] [105] [173] [174] [175]
Microglia	P2X₄-P2X₇ CB₁-CB₂ A_2A-CB₂ GPR₁₈-CB₂	Change of signaling pathways Antagonistic Reduced CB₂ signaling Cross-antagonism	[176] [177] [178] [179]

AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; IFNγ: interferon-γ receptor; D₁, D₂, D₅: type 1, 2, and 5 dopamine receptors; NMDA: N-methyl-D-aspartate glutamate receptor; MOR: μ-opiod receptor; A₁, A_2A: type 1 and 2A adenosine receptors; mGluR: metabotropic glutamate receptor; H₃: type 3 histamine receptor; 5HT_2A: type 2A serotonin receptor; GABA_A: type A gamma-aminobutyric-acid receptor; GR: glucocorticoid receptor; MR: mineralocorticoid receptor; ER_α: type α estrogen receptor; P2X, P2Y: purinergic ionotropic and G protein-coupled receptors; OTR: oxytocin receptor; CB₁, CB₂: type 1 and 2 cannabinoid receptors; GPR₁₈: G protein-coupled receptor 18

Declarations

Author contributions

DG: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Supervision. CT, CC, and MM: Investigation. GM and RDC: Writing—review & editing. LFA: Conceptualization, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Prezeau L, Rives ML, Comps-Agrar L, Maurel D, Kniazeff J, Pin JP. Functional crosstalk between GPCRs: with or without oligomerization. Curr Opin Pharmacol. 2010;10:6–13. [DOI] [PubMed]

Fuxe K, Agnati LF, Benfenati F, Celani M, Zini I, Zoli M, et al. Evidence for the existence of receptor--receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J Neural Transm Suppl. 1983;18:165–79. [PubMed]

Agnati LF, Fuxe K, Zini I, Lenzi P, Hökfelt T. Aspects on receptor regulation and isoreceptor identification. Med Biol. 1980;58:182–7. [PubMed]

Agnati LF, Fuxe K, Giardino L, Calza L, Zoli M, Battistini N, et al. Evidence for cholecystokinin-dopamine receptor interactions in the central nervous system of the adult and old rat. Studies on their functional meaning. Ann N Y Acad Sci. 1985;448:315–33. [DOI] [PubMed]

Fuxe K, Canals M, Torvinen M, Marcellino D, Terasmaa A, Genedani S, et al. Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J Neural Transm (Vienna). 2007;114:49–75. [DOI] [PubMed]

Kenakin T, Agnati LF, Caron M, Fredholm B, Guidoli D, Kobilka B, et al. International Workshop at the Nobel Forum, Karolinska Institutet on G protein-coupled receptors: finding the words to describe monomers, oligomers, and their molecular mechanisms and defining their meaning. Can a consensus be reached? J Recept Signal Transduct Res. 2010;30:284–6. [DOI] [PubMed]

Guidolin D, Tortorella C, Marcoli M, Maura G, Agnati LF. Intercellular Communication in the Central Nervous System as Deduced by Chemical Neuroanatomy and Quantitative Analysis of Images: Impact on Neuropharmacology. Int J Mol Sci. 2022;23:5805. [DOI] [PubMed] [PMC]

Trifilieff P, Rives ML, Urizar E, Piskorowski RA, Vishwasrao HD, Castrillon J, et al. Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. Biotechniques. 2011;51:111–8. [DOI] [PubMed] [PMC]

Fernández-Dueñas V, Gómez-Soler M, Valle-León M, Watanabe M, Ferrer I, Ciruela F. Revealing Adenosine A_2A-Dopamine D₂ Receptor Heteromers in Parkinson’s Disease Post-Mortem Brain through a New AlphaScreen-Based Assay. Int J Mol Sci. 2019;20:3600. [DOI] [PubMed] [PMC]

10.

Petazzi RA, Aji AK, Chiantia S. Fluorescence microscopy methods for the study of protein oligomerization. Prog Mol Biol Transl Sci. 2020;169:1–41. [DOI] [PubMed]

11.

De Oliveira PA, Moreno E, Casajuana-Martin N, Casadó-Anguera V, Cai NS, Camacho-Hernandez GA, et al. Preferential Gs protein coupling of the galanin Gal₁ receptor in the µ-opioid-Gal₁ receptor heterotetramer. Pharmacol Res. 2022;182:106322. [DOI] [PubMed] [PMC]

12.

Changeux JP, Christopoulos A. Allosteric modulation as a unifying mechanism for receptor function and regulation. Diabetes Obes Metab. 2017;19:4–21. [DOI] [PubMed]

13.

Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev. 2010;62:265–304. [DOI] [PubMed] [PMC]

14.

Smith NJ, Milligan G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev. 2010;62:701–25. [DOI] [PubMed] [PMC]

15.

Liu J, Nussinov R. Allostery: An Overview of Its History, Concepts, Methods, and Applications. PLoS Comput Biol. 2016;12:e1004966. [DOI] [PubMed] [PMC]

16.

Agnati LF, Guidolin D, Leo G, Carone C, Genedani S, Fuxe K. Receptor-receptor interactions: A novel concept in brain integration. Prog Neurobiol. 2010;90:157–75. [DOI] [PubMed]

17.

Filizola M, Weinstein H. The study of G-protein coupled receptor oligomerization with computational modeling and bioinformatics. FEBS J. 2005;272:2926–38. [DOI] [PubMed]

18.

Simpson LM, Taddese B, Wall ID, Reynolds CA. Bioinformatics and molecular modelling approaches to GPCR oligomerization. Curr Opin Pharmacol. 2010;10:30–7. [DOI] [PubMed]

19.

Guidolin D, Ciruela F, Genedani S, Guescini M, Tortorella C, Albertin G, et al. Bioinformatics and mathematical modelling in the study of receptor-receptor interactions and receptor oligomerization: focus on adenosine receptors. Biochim Biophys Acta. 2011;1808:1267–83. [DOI] [PubMed]

20.

Borroto-Escuela DO, Tarakanov AO, Brito I, Fuxe K. Glutamate heteroreceptor complexes in the brain. Pharmacol Rep. 2018;70:936–50. [DOI] [PubMed]

21.

Carriba P, Navarro G, Ciruela F, Ferré S, Casadó V, Agnati L, et al. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods. 2008;5:727–33. [DOI] [PubMed]

22.

Pinna A, Bonaventura J, Farré D, Sánchez M, Simola N, Mallol J, et al. L-DOPA disrupts adenosine A_2A-cannabinoid CB₁-dopamine D₂ receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp Neurol. 2014;253:180–91. [DOI] [PubMed]

23.

Cabello N, Gandía J, Bertarelli DC, Watanabe M, Lluís C, Franco R, et al. Metabotropic glutamate type 5, dopamine D₂ and adenosine A_2a receptors form higher-order oligomers in living cells. J Neurochem. 2009;109:1497–507. [DOI] [PubMed] [PMC]

24.

Beggiato S, Tomasini MC, Borelli AC, Borroto-Escuela DO, Fuxe K, Antonelli T, et al. Functional role of striatal A2A, D2, and mGlu5 receptor interactions in regulating striatopallidal GABA neuronal transmission. J Neurochem. 2016;138:254–64. [DOI] [PubMed]

25.

Borroto-Escuela DO, Cuesta-Marti C, Lopez-Salas A, Chruścicka-Smaga B, Crespo-Ramírez M, Tesoro-Cruz E, et al. The oxytocin receptor represents a key hub in the GPCR heteroreceptor network: potential relevance for brain and behavior. Front Mol Neurosci. 2022;15:1055344. [DOI] [PubMed] [PMC]

26.

Fuxe K, Agnati LF. Receptor-receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med Res Rev. 1985;5:441–82. [DOI] [PubMed]

27.

Zoli M, Guidolin D, Fuxe K, Agnati LF. The receptor mosaic hypothesis of the engram: possible relevance of Boolean network modeling. Int J Neural Syst. 1996;7:363–8. [DOI] [PubMed]

28.

Fuxe K, Borroto-Escuela DO, Ciruela F, Guidolin D, Agnati LF. Receptor-receptor interactions in heteroreceptor complexes: a new principle in biology. Focus on their role in learning and memory. Neurosci Discov. 2014;2:6. [DOI]

29.

Fuxe K, Borroto-Escuela DO. Volume transmission and receptor-receptor interactions in heteroreceptor complexes: understanding the role of new concepts for brain communication. Neural Regen Res. 2016;11:1220–3. [DOI] [PubMed] [PMC]

30.

Guidolin D, Marcoli M, Tortorella C, Maura G, Agnati LF. Receptor-Receptor Interactions as a Widespread Phenomenon: Novel Targets for Drug Development? Front Endocrinol (Lausanne). 2019;10:53. [DOI] [PubMed] [PMC]

31.

Fuxe K, Marcellino D, Guidolin D, Woods AS, Agnati L. Brain receptor mosaics and their intramembrane receptor-receptor interactions: molecular integration in transmission and novel targets for drug development. J Acupunct Meridian Stud. 2009;2:1–25. [DOI] [PubMed]

32.

Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004;27:107–44. [DOI] [PubMed]

33.

Ferrada C, Moreno E, Casadó V, Bongers G, Cortés A, Mallol J, et al. Marked changes in signal transduction upon heteromerization of dopamine D₁ and histamine H₃ receptors. Br J Pharmacol. 2009;157:64–75. [DOI] [PubMed] [PMC]

34.

Smith JS, Rajagopal S. The β-Arrestins: Multifunctional Regulators of G Protein-coupled Receptors. J Biol Chem. 2016;291:8969–77. [DOI] [PubMed] [PMC]

35.

Cervetto C, Venturini A, Guidolin D, Maura G, Passalacqua M, Tacchetti C, et al. Homocysteine and A2A-D2 Receptor-Receptor Interaction at Striatal Astrocyte Processes. J Mol Neurosci. 2018;65:456–66. [DOI] [PubMed]

36.

Romero GG. The Role of the Cell Background in Biased Signaling. In: Arey BJ, editor. Biased Signaling in Physiology, Pharmacology and Therapeutics. San Diego: Academic Press; 2014. pp. 41–79. [DOI]

37.

Franco R, Lluis C, Canela EI, Mallol J, Agnati L, Casadó V, et al. Receptor-receptor interactions involving adenosine A₁ or dopamine D₁ receptors and accessory proteins. J Neural Transm (Vienna). 2007;114:93–104. [DOI] [PubMed]

38.

Farran B. An update on the physiological and therapeutic relevance of GPCR oligomers. Pharmacol Res. 2017;117:303–27. [DOI] [PubMed]

39.

Borroto-Escuela DO, Carlsson J, Ambrogini P, Narváez M, Wydra K, Tarakanov AO, et al. Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease. Front Cell Neurosci. 2017;11:37. [DOI] [PubMed] [PMC]

40.

Guidolin D, Marcoli M, Maura G, Agnati LF. New dimensions of connectomics and network plasticity in the central nervous system. Rev Neurosci. 2017;28:113–32. [DOI] [PubMed]

41.

Kasai RS, Ito SV, Awane RM, Fujiwara TK, Kusumi A. The Class-A GPCR Dopamine D2 Receptor Forms Transient Dimers Stabilized by Agonists: Detection by Single-Molecule Tracking. Cell Biochem Biophys. 2018;76:29–37. [DOI] [PubMed] [PMC]

42.

Kleinau G, Müller A, Biebermann H. Oligomerization of GPCRs involved in endocrine regulation. J Mol Endocrinol. 2016;57:R59–80. [DOI] [PubMed]

43.

Fuxe K, Marcellino D, Rivera A, Diaz-Cabiale Z, Filip M, Gago B, et al. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev. 2008;58:415–52. [DOI] [PubMed]

44.

Ferré S, Belcher AM, Bonaventura J, Quiroz C, Sánchez-Soto M, Casadó-Anguera V, et al. Functional and pharmacological role of the dopamine D₄ receptor and its polymorphic variants. Front Endocrinol (Lausanne). 2022;13:1014678. [DOI] [PubMed] [PMC]

45.

Cervetto C, Maura G, Guidolin D, Amato S, Ceccoli C, Agnati LF, et al. Striatal astrocytic A2A-D2 receptor-receptor interactions and their role in neuropsychiatric disorders. Neuropharmacology. 2023;237:109636. [DOI] [PubMed]

46.

Romero-Fernandez W, Carvajal-Tapia C, Prusky A, Katdare KA, Wang E, Shostak A, et al. Detection, visualization and quantification of protein complexes in human Alzheimer’s disease brains using proximity ligation assay. Sci Rep. 2023;13:11948. [DOI] [PubMed] [PMC]

47.

Guidolin D, Tortorella C, Marcoli M, Cervetto C, De Caro R, Maura G, et al. Modulation of Neuron and Astrocyte Dopamine Receptors via Receptor-Receptor Interactions. Pharmaceuticals (Basel). 2023;16:1427. [DOI] [PubMed] [PMC]

48.

Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A. 2005;102:19208–13. [DOI] [PubMed] [PMC]

49.

Agnati LF, Ferré S, Genedani S, Leo G, Guidolin D, Filaferro M, et al. Allosteric modulation of dopamine D₂ receptors by homocysteine. J Proteome Res. 2006;5:3077–83. [DOI] [PubMed]

50.

Jonas KC, Hanyaloglu AC. Impact of G protein-coupled receptor heteromers in endocrine systems. Mol Cell Endocrinol. 2017;449:21–7. [DOI] [PubMed]

51.

Chen JF, Cunha RA. The belated US FDA approval of the adenosine A_2A receptor antagonist istradefylline for treatment of Parkinson’s disease. Purinergic Signal. 2020;16:167–74. [DOI] [PubMed] [PMC]

52.

Franco R, Navarro G. Neuroprotection afforded by targeting G protein-coupled receptors in heteromers and by heteromer-selective drugs. Front Pharmacol. 2023;14:1222158. [DOI] [PubMed] [PMC]

53.

Mattson MP. Excitotoxicity. In: Fink G, editor. Stress: Physiology, Biochemistry, and Pathology. Cambridge: Academic Press; 2019. pp. 125–34. [DOI]

54.

Armada-Moreira A, Gomes JI, Pina CC, Savchak OK, Gonçalves-Ribeiro J, Rei N, et al. Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. Front Cell Neurosci. 2020;14:90. [DOI] [PubMed] [PMC]

55.

Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969;164:719–21. [DOI] [PubMed]

56.

Connolly NM, Prehn JH. The metabolic response to excitotoxicity - lessons from single-cell imaging. J Bioenerg Biomembr. 2015;47:75–88. [DOI] [PubMed]

57.

Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol. 2013;698:6–18. [DOI] [PubMed]

58.

Pellegrini-Giampietro DE, Cherici G, Alesiani M, Carla V, Moroni F. Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J Neurosci. 1990;10:1035–41. [DOI] [PubMed] [PMC]

59.

Prentice H, Modi JP, Wu JY. Mechanisms of Neuronal Protection against Excitotoxicity, Endoplasmic Reticulum Stress, and Mitochondrial Dysfunction in Stroke and Neurodegenerative Diseases. Oxid Med Cell Longev. 2015;2015:964518. [DOI] [PubMed] [PMC]

60.

Kraig RP, Petito CK, Plum F, Pulsinelli WA. Hydrogen ions kill brain at concentrations reached in ischemia. J Cereb Blood Flow Metab. 1987;7:379–86. [DOI] [PubMed] [PMC]

61.

Zhang S, Sun P, Sun Z, Zhang J, Zhou J, Gu Y. Cortical GABAergic neurons are more severely impaired by alkalosis than acidosis. BMC Neurol. 2013;13:192. [DOI] [PubMed] [PMC]

62.

Sapolsky RM. Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion. Stress. 1996;1:1–19. [DOI] [PubMed]

63.

Mahmoud S, Gharagozloo M, Simard C, Gris D. Astrocytes Maintain Glutamate Homeostasis in the CNS by Controlling the Balance between Glutamate Uptake and Release. Cells. 2019;8:184. [DOI] [PubMed] [PMC]

64.

Sapolsky RM. Cellular defenses against excitotoxic insults. J Neurochem. 2001;76:1601–11. [DOI] [PubMed]

65.

Goyette MJ, Murray SL, Saldanha CJ, Holton K. Sex Hormones, Neurosteroids, and Glutamatergic Neurotransmission: A Review of the Literature. Neuroendocrinology. 2023;113:905–14. [DOI] [PubMed]

66.

Reiner A, Levitz J. Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron. 2018;98:1080–98. [DOI] [PubMed] [PMC]

67.

Purves D, Augustine GJ, Fitzpatrick D, Katz LC, LaMantia AS, McNamara JO, et al., editors. Neuroscience. 2nd ed. Sunderland: Sinauer Associates; 2001.

68.

Guo H, Camargo LM, Yeboah F, Digan ME, Niu H, Pan Y, et al. A NMDA-receptor calcium influx assay sensitive to stimulation by glutamate and glycine/D-serine. Sci Rep. 2017;7:11608. [DOI] [PubMed] [PMC]

69.

Chen PE, Geballe MT, Stansfeld PJ, Johnston AR, Yuan H, Jacob AL, et al. Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol. 2005;67:1470–84. [DOI] [PubMed]

70.

Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682–96. [DOI] [PubMed] [PMC]

71.

Pál B. Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability. Cell Mol Life Sci. 2018;75:2917–49. [DOI] [PubMed] [PMC]

72.

Wright A, Vissel B. The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. Front Mol Neurosci. 2012;5:34. [DOI] [PubMed] [PMC]

73.

Hume RI, Dingledine R, Heinemann SF. Identification of a site in glutamate receptor subunits that controls calcium permeability. Science. 1991;253:1028–31. [DOI] [PubMed]

74.

Huettner JE. Kainate receptors and synaptic transmission. Prog Neurobiol. 2003;70:387–407. [DOI] [PubMed]

75.

Chittajallu R, Vignes M, Dev KK, Barnes JM, Collingridge GL, Henley JM. Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature. 1996;379:78–81. [DOI] [PubMed]

76.

Castillo PE, Malenka RC, Nicoll RA. Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons. Nature. 1997;388:182–6. [DOI] [PubMed]

77.

Fauré J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, et al. Exosomes are released by cultured cortical neurones. Mol Cell Neurosci. 2006;31:642–8. [DOI] [PubMed]

78.

Agnati LF, Guidolin D, Guescini M, Genedani S, Fuxe K. Understanding wiring and volume transmission. Brain Res Rev. 2010;64:137–59. [DOI] [PubMed]

79.

Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol. 2010;50:295–322. [DOI] [PubMed] [PMC]

80.

Skeberdis VA, Lan J, Opitz T, Zheng X, Bennett MV, Zukin RS. mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C. Neuropharmacology. 2001;40:856–65. [DOI] [PubMed]

81.

Lea PM, Custer SJ, Vicini S, Faden AI. Neuronal and glial mGluR5 modulation prevents stretch-induced enhancement of NMDA receptor current. Pharmacol Biochem Behav. 2002;73:287–98. [DOI] [PubMed]

82.

Ambrosini A, Bresciani L, Fracchia S, Brunello N, Racagni G. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro. Mol Pharmacol. 1995;47:1057–64. [PubMed]

83.

McEwen BS. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann N Y Acad Sci. 2004;1032:1–7. [DOI] [PubMed]

84.

Koning ACAM, Buurstede JC, van Weert LTCM, Meijer OC. Glucocorticoid and Mineralocorticoid Receptors in the Brain: A Transcriptional Perspective. J Endocr Soc. 2019;3:1917–30. [DOI] [PubMed] [PMC]

85.

Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol. 2013;132:1033–44. [DOI] [PubMed] [PMC]

86.

Xiao X, Zhang H, Wang H, Li Q, Zhang T. Neuroprotective effect of amantadine on corticosterone-induced abnormal glutamatergic synaptic transmission of CA3-CA1 pathway in rat’s hippocampal slices. Synapse. 2017;71:e22010. [DOI] [PubMed]

87.

Di S, Malcher-Lopes R, Halmos KC, Tasker JG. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci. 2003;23:4850–7. [DOI] [PubMed] [PMC]

88.

Tasker JG, Di S, Malcher-Lopes R. Rapid central corticosteroid effects: evidence for membrane glucocorticoid receptors in the brain. Integr Comp Biol. 2005;45:665–71. [DOI] [PubMed]

89.

Herman JP. The neuroendocrinology of stress: Glucocorticoid signaling mechanisms. Psychoneuroendocrinology. 2022;137:105641. [DOI] [PubMed]

90.

Wang Y, Zhang Y, Hu J, Pan C, Gao Y, Liu Q, et al. Glucocorticoids modulate neural activity via a rapid non-genomic effect on Kv2.2 channels in the central nervous system. Neurobiol Stress. 2023;28:100593. [DOI] [PubMed] [PMC]

91.

Laudenbach V, Calo G, Guerrini R, Lamboley G, Benoist JF, Evrard P, et al. Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain. J Clin Invest. 2001;107:457–66. [DOI] [PubMed] [PMC]

92.

Sah P. Ca²⁺-activated K⁺ currents in neurones: types, physiological roles and modulation. Trends Neurosci. 1996;19:150–4. [DOI] [PubMed]

93.

Blatz AL, Magleby KL. Calcium-activated potassium channels. Trends Neurosci. 1987;10:463–7. [DOI]

94.

Honrath B, Krabbendam IE, Culmsee C, Dolga AM. Small conductance Ca²⁺-activated K⁺ channels in the plasma membrane, mitochondria and the ER: Pharmacology and implications in neuronal diseases. Neurochem Int. 2017;109:13–23. [DOI] [PubMed]

95.

Trapp S, Ballanyi K. KATP channel mediation of anoxia-induced outward current in rat dorsal vagal neurons in vitro. J Physiol. 1995;487:37–50. [DOI] [PubMed] [PMC]

96.

Bancila V, Nikonenko I, Dunant Y, Bloc A. Zinc inhibits glutamate release via activation of pre-synaptic K channels and reduces ischaemic damage in rat hippocampus. J Neurochem. 2004;90:1243–50. [DOI] [PubMed]

97.

Yenari MA, Giffard RG, Sapolsky RM, Steinberg GK. The neuroprotective potential of heat shock protein 70 (HSP70). Mol Med Today. 1999;5:525–31. [DOI] [PubMed]

98.

Cunha RA. Neuroprotection by adenosine in the brain: From A₁ receptor activation to A_2A receptor blockade. Purinergic Signal. 2005;1:111–34. [DOI] [PubMed] [PMC]

99.

Winkler P, Luhmann HJ, Kilb W. Taurine potentiates the anticonvulsive effect of the GABA_A agonist muscimol and pentobarbital in the immature mouse hippocampus. Epilepsia. 2019;60:464–74. [DOI] [PubMed]

100.

Samson AJ, Robertson G, Zagnoni M, Connolly CN. Neuronal networks provide rapid neuroprotection against spreading toxicity. Sci Rep. 2016;6:33746. [DOI] [PubMed] [PMC]

101.

Diano S, Naftolin F, Horvath TL. Gonadal steroids target AMPA glutamate receptor-containing neurons in the rat hypothalamus, septum and amygdala: a morphological and biochemical study. Endocrinology. 1997;138:778–89. [DOI] [PubMed]

102.

Gulinello M, Lebesgue D, Jover-Mengual T, Zukin RS, Etgen AM. Acute and chronic estradiol treatments reduce memory deficits induced by transient global ischemia in female rats. Horm Behav. 2006;49:246–60. [DOI] [PubMed] [PMC]

103.

Miller NR, Jover T, Cohen HW, Zukin RS, Etgen AM. Estrogen can act via estrogen receptor alpha and beta to protect hippocampal neurons against global ischemia-induced cell death. Endocrinology. 2005;146:3070–9. [DOI] [PubMed]

104.

Kofuji P, Araque A. G-Protein-Coupled Receptors in Astrocyte-Neuron Communication. Neuroscience. 2021;456:71–84. [DOI] [PubMed] [PMC]

105.

Cristóvão-Ferreira S, Navarro G, Brugarolas M, Pérez-Capote K, Vaz SH, Fattorini G, et al. A₁R-A_2AR heteromers coupled to G_s and G_i/0 proteins modulate GABA transport into astrocytes. Purinergic Signal. 2013;9:433–49. [DOI] [PubMed] [PMC]

106.

Cuellar-Santoyo AO, Ruiz-Rodríguez VM, Mares-Barbosa TB, Patrón-Soberano A, Howe AG, Portales-Pérez DP, et al. Revealing the contribution of astrocytes to glutamatergic neuronal transmission. Front Cell Neurosci. 2023;16:1037641. [DOI] [PubMed] [PMC]

107.

Okubo Y, Sekiya H, Namiki S, Sakamoto H, Iinuma S, Yamasaki M, et al. Imaging extrasynaptic glutamate dynamics in the brain. Proc Natl Acad Sci U S A. 2010;107:6526–31. [DOI] [PubMed] [PMC]

108.

Eulenburg V, Gomeza J. Neurotransmitter transporters expressed in glial cells as regulators of synapse function. Brain Res Rev. 2010;63:103–12. [DOI] [PubMed]

109.

Rodríguez-Arellano JJ, Parpura V, Zorec R, Verkhratsky A. Astrocytes in physiological aging and Alzheimer’s disease. Neuroscience. 2016;323:170–82. [DOI] [PubMed]

110.

Waniewski RA, Martin DL. Exogenous glutamate is metabolized to glutamine and exported by rat primary astrocyte cultures. J Neurochem. 1986;47:304–13. [DOI] [PubMed]

111.

Guidolin D, Tortorella C, Marcoli M, Cervetto C, Maura G, Agnati LF. Receptor-receptor interactions and microvesicle exchange as mechanisms modulating signaling between neurons and astrocytes. Neuropharmacology. 2023;231:109509. [DOI] [PubMed]

112.

Fan D, Grooms SY, Araneda RC, Johnson AB, Dobrenis K, Kessler JA, et al. AMPA receptor protein expression and function in astrocytes cultured from hippocampus. J Neurosci Res. 1999;57:557–71. [PubMed]

113.

Belov Kirdajova D, Kriska J, Tureckova J, Anderova M. Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells. Front Cell Neurosci. 2020;14:51. [DOI] [PubMed] [PMC]

114.

Palygin O, Lalo U, Pankratov Y. Distinct pharmacological and functional properties of NMDA receptors in mouse cortical astrocytes. Br J Pharmacol. 2011;163:1755–66. [DOI] [PubMed] [PMC]

115.

Lalo U, Pankratov Y, Kirchhoff F, North RA, Verkhratsky A. NMDA receptors mediate neuron-to-glia signaling in mouse cortical astrocytes. J Neurosci. 2006;26:2673–83. [DOI] [PubMed] [PMC]

116.

Liang Z, Valla J, Sefidvash-Hockley S, Rogers J, Li R. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer’s disease patients. J Neurochem. 2002;80:807–14. [DOI] [PubMed]

117.

Nematipour S, Vahidinia Z, Nejati M, Naderian H, Beyer C, Azami Tameh A. Estrogen and progesterone attenuate glutamate neurotoxicity via regulation of EAAT3 and GLT-1 in a rat model of ischemic stroke. Iran J Basic Med Sci. 2020;23:1346–52. [DOI] [PubMed] [PMC]

118.

Matos M, Augusto E, Agostinho P, Cunha RA, Chen JF. Antagonistic interaction between adenosine A_2A receptors and Na⁺/K⁺-ATPase-α2 controlling glutamate uptake in astrocytes. J Neurosci. 2013;33:18492–502. [DOI] [PubMed] [PMC]

119.

Malarkey EB, Parpura V. Mechanisms of glutamate release from astrocytes. Neurochem Int. 2008;52:142–54. [DOI] [PubMed] [PMC]

120.

de Ceglia R, Ledonne A, Litvin DG, Lind BL, Carriero G, Latagliata EC, et al. Specialized astrocytes mediate glutamatergic gliotransmission in the CNS. Nature. 2023;622:120–9. [DOI] [PubMed] [PMC]

121.

Harada K, Kamiya T, Tsuboi T. Gliotransmitter Release from Astrocytes: Functional, Developmental, and Pathological Implications in the Brain. Front Neurosci. 2016;9:499. [DOI] [PubMed] [PMC]

122.

Borroto-Escuela DO, Hinz S, Navarro G, Franco R, Müller CE, Fuxe K. Understanding the Role of Adenosine A2AR Heteroreceptor Complexes in Neurodegeneration and Neuroinflammation. Front Neurosci. 2018;12:43. [DOI] [PubMed] [PMC]

123.

Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci. 2009;10:561–72. [DOI] [PubMed]

124.

Lee S, Yoon BE, Berglund K, Oh SJ, Park H, Shin HS, et al. Channel-mediated tonic GABA release from glia. Science. 2010;330:790–6. [DOI] [PubMed]

125.

Mason S. Lactate Shuttles in Neuroenergetics-Homeostasis, Allostasis and Beyond. Front Neurosci. 2017;11:43. [DOI] [PubMed] [PMC]

126.

Schousboe A, Westergaard N, Waagepetersen HS, Larsson OM, Bakken IJ, Sonnewald U. Trafficking between glia and neurons of TCA cycle intermediates and related metabolites. Glia. 1997;21:99–105. [PubMed]

127.

Eggen BJL, Raj D, Hanisch UK, Boddeke HW. Microglial phenotype and adaptation. J Neuroimmune Pharmacol. 2013;8:807–23. [DOI] [PubMed]

128.

Maeda J, Minamihisamatsu T, Shimojo M, Zhou X, Ono M, Matsuba Y, et al. Distinct microglial response against Alzheimer’s amyloid and tau pathologies characterized by P2Y12 receptor. Brain Commun. 2021;3:fcab011. [DOI] [PubMed] [PMC]

129.

Chidambaram H, Das R, Chinnathambi S. G-protein coupled purinergic P2Y12 receptor interacts and internalizes Tau^RD-mediated by membrane-associated actin cytoskeleton remodeling in microglia. Eur J Cell Biol. 2022;101:151201. [DOI] [PubMed]

130.

Franco R, Fernández-Suárez D. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol. 2015;131:65–86. [DOI] [PubMed]

131.

Zhang X, Wang D, Zhang B, Zhu J, Zhou Z, Cui L. Regulation of microglia by glutamate and its signal pathway in neurodegenerative diseases. Drug Discov Today. 2020;25:1074–85. [DOI] [PubMed]

132.

Kim CC, Nakamura MC, Hsieh CL. Brain trauma elicits non-canonical macrophage activation states. J Neuroinflammation. 2016;13:117. [DOI] [PubMed] [PMC]

133.

Domercq M, Vázquez-Villoldo N, Matute C. Neurotransmitter signaling in the pathophysiology of microglia. Front Cell Neurosci. 2013;7:49. [DOI] [PubMed] [PMC]

134.

Kaindl AM, Degos V, Peineau S, Gouadon E, Chhor V, Loron G, et al. Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Ann Neurol. 2012;72:536–49. [DOI] [PubMed]

135.

Kumar A, Dhull DK, Mishra PS. Therapeutic potential of mGluR5 targeting in Alzheimer’s disease. Front Neurosci. 2015;9:215. [DOI] [PubMed] [PMC]

136.

Taylor DL, Diemel LT, Pocock JM. Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci. 2003;23:2150–60. [DOI] [PubMed] [PMC]

137.

Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol. 2014;115:157–88. [DOI] [PubMed]

138.

O’Donovan SM, Sullivan CR, McCullumsmith RE. The role of glutamate transporters in the pathophysiology of neuropsychiatric disorders. NPJ Schizophr. 2017;3:32. [DOI] [PubMed] [PMC]

139.

Albrecht J, Zielińska M. Mechanisms of Excessive Extracellular Glutamate Accumulation in Temporal Lobe Epilepsy. Neurochem Res. 2017;42:1724–34. [DOI] [PubMed]

140.

Peterson AR, Binder DK. Regulation of Synaptosomal GLT-1 and GLAST during Epileptogenesis. Neuroscience. 2019;411:185–201. [DOI] [PubMed]

141.

Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627–38. [DOI] [PubMed] [PMC]

142.

Texidó L, Martín-Satué M, Alberdi E, Solsona C, Matute C. Amyloid β peptide oligomers directly activate NMDA receptors. Cell Calcium. 2011;49:184–90. [DOI] [PubMed]

143.

Angelova PR, Abramov AY. Interaction of neurons and astrocytes underlies the mechanism of Aβ-induced neurotoxicity. Biochem Soc Trans. 2014;42:1286–90. [DOI] [PubMed]

144.

Dienel GA. The metabolic trinity, glucose-glycogen-lactate, links astrocytes and neurons in brain energetics, signaling, memory, and gene expression. Neurosci Lett. 2017;637:18–25. [DOI] [PubMed]

145.

Arnold FJ, Putka AF, Raychaudhuri U, Hsu S, Bedlack RS, Bennett CL, et al. Revisiting Glutamate Excitotoxicity in Amyotrophic Lateral Sclerosis and Age-Related Neurodegeneration. Int J Mol Sci. 2024;25:5587. [DOI] [PubMed] [PMC]

146.

Bae JS, Simon NG, Menon P, Vucic S, Kiernan MC. The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol. 2013;9:65–74. [DOI] [PubMed] [PMC]

147.

Glaser T, Silva JB, Juvenal GA, Maiolini PN, Turrini N, Petiz LL, et al. Various facets of excitotoxicity. Explor Neuroprot Ther. 2022;2:36–64. [DOI]

148.

Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, et al. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity. PLoS One. 2010;5:e14020. [DOI] [PubMed] [PMC]

149.

Fan J, Cowan CM, Zhang LY, Hayden MR, Raymond LA. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington’s disease. J Neurosci. 2009;29:10928–38. [DOI] [PubMed] [PMC]

150.

Mizuno T, Zhang G, Takeuchi H, Kawanokuchi J, Wang J, Sonobe Y, et al. Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor. FASEB J. 2008;22:1797–806. [DOI] [PubMed]

151.

Zou S, Li L, Pei L, Vukusic B, Van Tol HH, Lee FJ, et al. Protein-protein coupling/uncoupling enables dopamine D₂ receptor regulation of AMPA receptor-mediated excitotoxicity. J Neurosci. 2005;25:4385–95. [DOI] [PubMed] [PMC]

152.

Lee FJ, Xue S, Pei L, Vukusic B, Chéry N, Wang Y, et al. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell. 2002;111:219–30. [DOI] [PubMed]

153.

Liu XY, Chu XP, Mao LM, Wang M, Lan HX, Li MH, et al. Modulation of D2R-NR2B interactions in response to cocaine. Neuron. 2006;52:897–909. [DOI] [PubMed]

154.

Rodríguez-Muñoz M, Sánchez-Blázquez P, Vicente-Sánchez A, Berrocoso E, Garzón J. The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. Neuropsychopharmacology. 2012;37:338–49. [DOI] [PubMed] [PMC]

155.

Franco R, Rivas-Santisteban R, Casanovas M, Lillo A, Saura CA, Navarro G. Adenosine A_2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer’s Disease. Cells. 2020;9:1075. [DOI] [PubMed] [PMC]

156.

Perroy J, Raynaud F, Homburger V, Rousset M, Telley L, Bockaert J, et al. Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors. J Biol Chem. 2008;283:6799–805. [DOI] [PubMed]

157.

Rodríguez-Ruiz M, Moreno E, Moreno-Delgado D, Navarro G, Mallol J, Cortés A, et al. Heteroreceptor Complexes Formed by Dopamine D₁, Histamine H₃, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer’s Disease. Mol Neurobiol. 2017;54:4537–50. [DOI] [PubMed]

158.

Pandya NJ, Klaassen RV, van der Schors RC, Slotman JA, Houtsmuller A, Smit AB, et al. Group 1 metabotropic glutamate receptors 1 and 5 form a protein complex in mouse hippocampus and cortex. Proteomics. 2016;16:2698–705. [DOI] [PubMed] [PMC]

159.

Wang X, Wang M, Xu T, Feng Y, Shao Q, Han S, et al. Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers. Cell Res. 2023;33:762–74. [DOI] [PubMed] [PMC]

160.

Habrian CH, Levitz J, Vyklicky V, Fu Z, Hoagland A, McCort-Tranchepain I, et al. Conformational pathway provides unique sensitivity to a synaptic mGluR. Nat Commun. 2019;10:5572. [DOI] [PubMed] [PMC]

161.

Kamikubo Y, Tabata T, Sakairi H, Hashimoto Y, Sakurai T. Complex formation and functional interaction between adenosine A1 receptor and type-1 metabotropic glutamate receptor. J Pharmacol Sci. 2015;128:125–30. [DOI] [PubMed]

162.

González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008;452:93–7. [DOI] [PubMed] [PMC]

163.

Ferré S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueño J, Gutiérrez MA, et al. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci U S A. 2002;99:11940–5. [DOI] [PubMed] [PMC]

164.

Tebano MT, Martire A, Rebola N, Pepponi R, Domenici MR, Grò MC, et al. Adenosine A_2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects. J Neurochem. 2005;95:1188–200. [DOI] [PubMed]

165.

Popoli P, Pèzzola A, Torvinen M, Reggio R, Pintor A, Scarchilli L, et al. The selective mGlu₅receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D₂ receptors in the rat striatum: interactions with adenosine A_2areceptors. Neuropsychopharmacology. 2001;25:505–13. [DOI] [PubMed]

166.

Schröder H, Wu DF, Seifert A, Rankovic M, Schulz S, Höllt V, et al. Allosteric modulation of metabotropic glutamate receptor 5 affects phosphorylation, internalization, and desensitization of the micro-opioid receptor. Neuropharmacology. 2009;56:768–78. [DOI] [PubMed]

167.

Ferre S, Ciruela F, Borycz J, Solinas M, Quarta D, Antoniou K, et al. Adenosine A₁-A_2Areceptor heteromers: new targets for caffeine in the brain. Front Biosci. 2008;13:2391–9. [DOI] [PubMed]

168.

Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature. 2000;403:274–80. [DOI] [PubMed]

169.

Batalha VL, Ferreira DG, Coelho JE, Valadas JS, Gomes R, Temido-Ferreira M, et al. The caffeine-binding adenosine A_2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function. Sci Rep. 2016;6:31493. [DOI] [PubMed] [PMC]

170.

Mifsud KR, Reul JM. Acute stress enhances heterodimerization and binding of corticosteroid receptors at glucocorticoid target genes in the hippocampus. Proc Natl Acad Sci U S A. 2016;113:11336–41. [DOI] [PubMed] [PMC]

171.

Dewing P, Boulware MI, Sinchak K, Christensen A, Mermelstein PG, Micevych P. Membrane estrogen receptor-alpha interactions with metabotropic glutamate receptor 1a modulate female sexual receptivity in rats. J Neurosci. 2007;27:9294–300. [DOI] [PubMed] [PMC]

172.

Pelassa S, Guidolin D, Venturini A, Averna M, Frumento G, Campanini L, et al. A2A-D2 Heteromers on Striatal Astrocytes: Biochemical and Biophysical Evidence. Int J Mol Sci. 2019;20:2457. [DOI] [PubMed] [PMC]

173.

Tonazzini I, Trincavelli ML, Montali M, Martini C. Regulation of A₁ adenosine receptor functioning induced by P2Y₁ purinergic receptor activation in human astroglial cells. J Neurosci Res. 2008;86:2857–66. [DOI] [PubMed]

174.

Amato S, Averna M, Guidolin D, Pedrazzi M, Pelassa S, Capraro M, et al. Heterodimer of A2A and Oxytocin Receptors Regulating Glutamate Release in Adult Striatal Astrocytes. Int J Mol Sci. 2022;23:2326. [DOI] [PubMed] [PMC]

175.

Amato S, Averna M, Guidolin D, Ceccoli C, Gatta E, Candiani S, et al. Heteromerization of Dopamine D2 and Oxytocin Receptor in Adult Striatal Astrocytes. Int J Mol Sci. 2023;24:4677. [DOI] [PubMed] [PMC]

176.

Guo C, Masin M, Qureshi OS, Murrell-Lagnado RD. Evidence for functional P2X₄/P2X₇ heteromeric receptors. Mol Pharmacol. 2007;72:1447–56. [DOI] [PubMed]

177.

Callén L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortés A, Mallol J, et al. Cannabinoid receptors CB₁ and CB₂ form functional heteromers in brain. J Biol Chem. 2012;287:20851–65. [DOI] [PubMed] [PMC]

178.

Franco R, Reyes-Resina I, Aguinaga D, Lillo A, Jiménez J, Raïch I, et al. Potentiation of cannabinoid signaling in microglia by adenosine A_2Areceptor antagonists. Glia. 2019;67:2410–23. [DOI] [PubMed]

179.

Reyes-Resina I, Navarro G, Aguinaga D, Canela EI, Schoeder CT, Załuski M, et al. Molecular and functional interaction between GPR18 and cannabinoid CB₂G-protein-coupled receptors. Relevance in neurodegenerative diseases. Biochem Pharmacol. 2018;157:169–79. [DOI] [PubMed]

180.

Nicoletti F, Di Menna L, Iacovelli L, Orlando R, Zuena AR, Conn PJ, et al. GPCR interactions involving metabotropic glutamate receptors and their relevance to the pathophysiology and treatment of CNS disorders. Neuropharmacology. 2023;235:109569. [DOI] [PubMed]

181.

Liu J, Zhang Z, Moreno-Delgado D, Dalton JA, Rovira X, Trapero A, et al. Allosteric control of an asymmetric transduction in a G protein-coupled receptor heterodimer. Elife. 2017;6:e26985. [DOI] [PubMed] [PMC]

182.

Murat S, Bigot M, Chapron J, König GM, Kostenis E, Battaglia G, et al. 5-HT_2A receptor-dependent phosphorylation of mGlu₂ receptor at Serine 843 promotes mGlu₂ receptor-operated G_i/o signaling. Mol Psychiatry. 2019;24:1610–26. [DOI] [PubMed]

183.

Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience. 2001;106:579–87. [DOI] [PubMed]

184.

Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci. 2000;3:661–9. [DOI] [PubMed]

185.

Scholler P, Nevoltris D, de Bundel D, Bossi S, Moreno-Delgado D, Rovira X, et al. Allosteric nanobodies uncover a role of hippocampal mGlu2 receptor homodimers in contextual fear consolidation. Nat Commun. 2017;8:1967. [DOI] [PubMed] [PMC]

186.

Borroto-Escuela DO, Rodriguez D, Romero-Fernandez W, Kapla J, Jaiteh M, Ranganathan A, et al. Mapping the Interface of a GPCR Dimer: A Structural Model of the A_2A Adenosine and D₂ Dopamine Receptor Heteromer. Front Pharmacol. 2018;9:829. [DOI] [PubMed] [PMC]

187.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–12. [DOI] [PubMed]

188.

de Mendonça A, Sebastião AM, Ribeiro JA. Adenosine: does it have a neuroprotective role after all? Brain Res Brain Res Rev. 2000;33:258–74. [DOI] [PubMed]

189.

Fuxe K, Marcellino D, Genedani S, Agnati L. Adenosine A_2A receptors, dopamine D₂ receptors and their interactions in Parkinson’s disease. Mov Disord. 2007;22:1990–2017. [DOI] [PubMed]

190.

Tozzi A, Tscherter A, Belcastro V, Tantucci M, Costa C, Picconi B, et al. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology. 2007;53:783–9. [DOI] [PubMed]

191.

Guidolin D, Marcoli M, Tortorella C, Maura G, Agnati LF. Adenosine A_2A-dopamine D₂ receptor-receptor interaction in neurons and astrocytes: Evidence and perspectives. Prog Mol Biol Transl Sci. 2020;169:247–77. [DOI] [PubMed]

192.

Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci U S A. 1991;88:7238–41. [DOI] [PubMed] [PMC]

193.

Kull B, Ferré S, Arslan G, Svenningsson P, Fuxe K, Owman C, et al. Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochem Pharmacol. 1999;58:1035–45. [DOI] [PubMed]

194.

Fernández-Dueñas V, Gómez-Soler M, Jacobson KA, Kumar ST, Fuxe K, Borroto-Escuela DO, et al. Molecular determinants of A_2AR-D₂R allosterism: role of the intracellular loop 3 of the D₂R. J Neurochem. 2012;123:373–84. [DOI] [PubMed] [PMC]

195.

Dominguez R, Micevych P. Estradiol rapidly regulates membrane estrogen receptor alpha levels in hypothalamic neurons. J Neurosci. 2010;30:12589–96. [DOI] [PubMed] [PMC]

196.

Guidolin D, Tortorella C, Marcoli M, Cervetto C, Maura G, Agnati LF. Receptor-Receptor Interactions and Glial Cell Functions with a Special Focus on G Protein-Coupled Receptors. Int J Mol Sci. 2021;22:8656. [DOI] [PubMed] [PMC]

197.

Cervetto C, Venturini A, Passalacqua M, Guidolin D, Genedani S, Fuxe K, et al. A2A-D2 receptor-receptor interaction modulates gliotransmitter release from striatal astrocyte processes. J Neurochem. 2017;140:268–79. [DOI] [PubMed]

198.

McNeill J, Rudyk C, Hildebrand ME, Salmaso N. Ion Channels and Electrophysiological Properties of Astrocytes: Implications for Emergent Stimulation Technologies. Front Cell Neurosci. 2021;15:644126. [DOI] [PubMed] [PMC]

199.

Fitzner D, Bader JM, Penkert H, Bergner CG, Su M, Weil MT, et al. Cell-Type- and Brain-Region-Resolved Mouse Brain Lipidome. Cell Rep. 2020;32:108132. [DOI] [PubMed]

200.

Tewari M, Michalski S, Egan TM. Modulation of Microglial Function by ATP-Gated P2X7 Receptors: Studies in Rat, Mice and Human. Cells. 2024;13:161. [DOI] [PubMed] [PMC]

201.

Trang M, Schmalzing G, Müller CE, Markwardt F. Dissection of P2X4 and P2X7 Receptor Current Components in BV-2 Microglia. Int J Mol Sci. 2020;21:8489. [DOI] [PubMed] [PMC]

202.

Tanaka M, Sackett S, Zhang Y. Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology. Front Neurol. 2020;11:87. [DOI] [PubMed] [PMC]

203.

Young AP, Denovan-Wright EM. The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation. Front Pharmacol. 2022;12:806417. [DOI] [PubMed] [PMC]

204.

Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58:1017–30. [DOI] [PubMed] [PMC]

205.

Lewerenz J, Maher P. Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence? Front Neurosci. 2015;9:469. [DOI] [PubMed] [PMC]

206.

Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther. 1999;81:163–221. [DOI] [PubMed]